{"id":"teneli-teneli-pio","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Weight gain (with pioglitazone component)"},{"rate":null,"effect":"Fluid retention (with pioglitazone component)"}]},"_chembl":{"chemblId":"CHEMBL5817272","moleculeType":null,"molecularWeight":"356.45"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Teneli inhibits dipeptidyl peptidase-4 (DPP-4), an enzyme that degrades incretin hormones (GLP-1 and GIP). By preventing incretin degradation, the drug prolongs their action, leading to glucose-dependent stimulation of insulin secretion and suppression of glucagon secretion. The combination formulation with pioglitazone (Teneli + pio) adds insulin sensitization through PPAR-γ activation.","oneSentence":"Teneli is a DPP-4 inhibitor that increases incretin levels to enhance insulin secretion and reduce glucagon in response to meals, improving glycemic control in type 2 diabetes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:38:01.779Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus (monotherapy and combination therapy)"}]},"trialDetails":[{"nctId":"NCT01026194","phase":"PHASE3","title":"Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-12","conditions":"Type 2 Diabetes Mellitus","enrollment":204}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1058,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Teneli / Teneli + pio","genericName":"Teneli / Teneli + pio","companyName":"Tanabe Pharma Corporation","companyId":"tanabe-pharma-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Teneligliptin (Teneli) is a medication used to treat Type 2 Diabetes Mellitus. It is studied in combination with pioglitazone (pio) for efficacy and safety in patients with Type 2 Diabetes, as part of a Phase III clinical trial.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}